Results 31 to 40 of about 132,691 (210)

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment

Journal of Enzyme Inhibition and Medicinal Chemistry, 2020
In this paper, a series of novel 3-methyl-quinazolinone derivatives was designed, synthesised and evaluated for antitumor activity in vitro on wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) and three human cancer cell lines ...
Yi Le, Yiyuan Gan, Yihong Fu, Jiamin Liu, Wen Li, Xue Zou, Zhixu Zhou, Zhenchao Wang, Guiping Ouyang, Longjia Yan   +9 more
doaj   +1 more source

GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

Сибирский онкологический журнал, 2020
Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov, V. M. Safronova, S. N. Nered, L. N. Lyubchenko, I. S. Stilidi   +4 more
doaj   +1 more source

Correlation of sonographic parameters with renal function in patients with newly diagnosed chronic kidney disease

Journal of Ultrasonography, 2022
To correlate sonographic renal parameters (mean renal cortical thickness, length and volume) with renal functions in patients with newly diagnosed chronic kidney disease.
Garg Aborishi, Jhobta Anupam, Kapila Sumala, Rathour Devesha   +3 more
doaj   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Nuclear EGFR modulation of DNA repair [PDF]

, 2011
Overexpression of the epidermal growth factor receptor (EGFR) is associated with resistance to chemotherapy and radiotherapy. EGFR involvement, in repair of radiation-induced DNA damage, is mediated by association with the catalytic subunit of DNA ...
Liccardi, G.
core  

EGFR-positive CTCs correlates with worse prognosis.

, 2016
A) EGFR-positive CTC enumeration from patients with colon, prostate and breast metastatic cancer (from Table 3); (Spearman rank correlation coefficient = 0.575 ...
Ana Vila (436509), Clotilde Costa (435855), Miguel Abal (152347), Rafael López-López (152343), Laura Muinelo-Romay (152313), Carlos Rodriguez-Abreu (843075), José Rivas (760818)   +6 more
core   +1 more source

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells [PDF]

, 2011
Background:The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer.
F Solca, Solca, F, D Mackintosh, Guertler, U, Modjtahedi, H, Mackintosh, D, A G Dalgleish, Seddon, AM, Dalgleish, AG, N Ioannou, A M Seddon, U Guertler, Ioannou, N, Dalgleish, A G, H Modjtahedi, Seddon, A M   +15 more
core   +1 more source

The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus

Journal of Family Medicine and Primary Care
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with kidney complications. This study aims to investigate the effects of weekly subcutaneous semaglutide, a GLP-1 agonist, on kidney outcomes.
Ahmad A Algarni, Fahad S Alqarni, Hanin A Shalaby   +2 more
doaj   +1 more source

Blockade of the P2Y2 Receptor Attenuates Alcoholic Liver Inflammation by Targeting the EGFR-ERK1/2 Signaling Pathway

Drug Design, Development and Therapy, 2022
Zhen-Ni Liu,1– 3,* Qian-Qian Su,4,* Yu-Hui Wang,1– 3,* Xue Wu,1– 3 Xiong-Wen Lv1– 3 1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University ...
Liu ZN, Su QQ, Wang YH, Wu X, Lv XW
doaj  

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source